ABSTRACT
INTRODUCTION
Antisense oligodeoxynucleotides within cells targeted toward the RNA transcript of a specific gene can inhibit the expression or promote the degradation of the transcript, resulting in suppression of the function coded for by the gene (1, 2) . Alternatively or additionally, the antisense oligodeoxynucleotides may also bind to the viral mRNA, thus forming an RNA/DNA hybrid and preventing translation of the viral mRNA. Antisense oligodeoxynucleotides have been used widely as tools for regulating specific gene expression (3) and for inhibiting viral replication (4) (5) (6) (7) . However, the susceptibility to degradation by nucleases of the phosphodiester linkage in the natural type of oligodeoxynucleotides suggests to reduce their potency and in vivo persistence as antiviral agents (8) . Therefore, considerable efforts have been made to develop chemically stable oligodeoxynucleotides which are nuclease-resistant, but retain their Watson-Crick base pairing specificity. While several types of chemically modified oligodeoxynucleotides have been synthesized, the most widely-used modifications are replacement of a backbone oxygen with sulfur to form phosphorothioate (9) (10) (11) , or the substitution of methyl residue to form a methylphosphonate (6, 12, 13) . Phosphorothioate oligodeoxynucleotides are more stable to cleavage by nucleases and, having the same number of charges as phosphodiester oligodeoxynucleotides, have good solubility. HIV replication was inhibited by phosphorothioate antisense oligodeoxynucleotides in either acute (9, 14, 15) or chronically infected cells (11, 16) . However, the control, nonsequence-specific phosphorothioate oligodeoxynucleotides showed anti-HTV activity as well. These finding cast doubt on the notion that S-ODNs act in an antisense manner. Recently, we demonstrated that S-ODNs inhibited polymerization by binding to the avian myeloblastosis virus (AMV) reverse transcriptase (RT) rather than to template RNA, whereas there was no competitive binding of S-ODNs to HTV RT during reverse transcription (17) . We present here data obtained through detailed observation of the cellular uptake and intracellular distribution of phosphorothioate oligodeoxynucleotides.
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MATERIALS AND METHODS Oligodeoxynucleotides
Antisense oligodeoxynucleotides used in the present study were complementary in sequence to the region of the translation start site of the rev gene, which is essential for viral replication (18) . The unmodified oligodeoxynucleotide (0-ODN-rev; 5'-TCT-CCGCTTCTTCCTGCCAT-3', 5550-5569) and modified oligodeoxynucleotides, in which whole intranucleotide phosphodiester linkages are replaced by phosphorothioate (5-ODN-rev; 5'-TsCsTsCsCsGsCsTsTsCsTsTsCsCsTsGsCsCsAsT-3') and only two intranucleotide linkages at both the 5'-and 3'-end are replaced by phosphorothioate (50-ODN-rev; 5'-TsCsTCCGCTTCTTCCTGCCsAsT-3'), were synthesized as described previously (14) . Phosphorothioate-modified antisense oligodeoxynucleotides against the region of the splicing acceptor site of the rev gene (S-ODN-rev-sa; 5'-GsGsAsGsAsTsGsCsCsTsAsAsGsGsCsTsTsTsTsG-3', 5529-5548), phosphorothioate-modified sense oligodeoxynucleotides (5-ODN-rev-w-sense; 5'-CsCsTsCsTsAsCsGsGsAsTsTsCsCsGsAsAsAsAsC-3') and phosphorothioate-modified mismatched oligodeoxynucleotides (5-0DN-rev-sa-mis; 5 '-CsCsTsGsTsAsCsGsCsAsTsTsCsCsCsAsAsTsAsC-3') were also synthesized. To clarify the sequence specificity, phosphorothioate random sequence (S-random, 5'-TsTsCsTsTsTsCsCsAsTsAsTsTsGsAsAsTsAsTsA-3'), 20-mer homooligomer oligo(dC) (S-dC20) and 20-mer homooligomer oligo(dT) (5-dT20) were synthesized, too.
Cells and virus
Human T-lymphotropic virus type I (HTLV-I) positive human T cell line, MT-4, and HTLV-I non-infected T cell line, MOLT-4, were grown and maintained in RPMI 1640 medium supplemented with 10% (vol./vol.) heat-inactivated fetal calf serum, 100 IU of penicillin per ml and 100 /xg of streptomycin per ml (the complete medium). A strain of HTV-1, HTLV-JJIB, was obtained from the culture supernatant of the chronically HIV-1-infected MOLT-4 cell, MOLT-4/HIV-l HTLV . I1IB , and stored in a small volume (1 ml) at -80°C until use. The titer of the virus stocks was determined as 50% tissue culture infectious doses (TCID 50 ).
Anti-HTV assay in HTV-induced cytopathic effects (CPE)
Anti-HIV activity of the test compounds was determined by the protection they provided from HTV-induced cytopathic effects (CPE). MT^ cells were infected with HTLV-IHB at a multiplicity of infection (MOI) of 0.01. HTV-infected MT-4 cells (1.5 X10 5 cells/ml, 200 fi\) were placed into 96-well microtiter plates and incubated in the presence of various concentrations of test compounds. All experiments were carried out in triplicate. After 5 days of culture at 37 C C in a CO 2 incubator, the number of viable cells was determined by the 3'-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method (19) . The cytotoxicities of the compounds were evaluated in parallel with their antiviral activities and was determined on the basis of the viability of mock-infected cells, as determined by the MTT method.
Assay for inhibition of viral expression in chronically HIVinfected cells
To test whether antisense oligodeoxynucleotides inhibit viral gene expression, we used chronically HIV-1-infected MOLT-4 cells.
MOLT-4/HTV-1 cells were extensively washed to remove the previously produced viral particles from the media. After washing, 30X10 4 cells/ml were cultured in the presence of various concentrations of 5-ODN-rev and cultured in a CO 2 incubator at 37°C. The cells were washed and the number of cells was adjusted to SOxlO^ml in fresh culture medium containing the same amounts of 5-ODN-rev, twice a week. The number of viable cells and amount of p24 gag protein in the culture supernatant were monitored by trypan blue dye exclusion method and HIV-1 p24 assay kit (Abbott GmgH Diagnostika, Wiesbaden-Delkenheim, Germany), respectively, on day 2, 4 and 20 after incubation.
Reverse transcriptase (RT) assay
The effect of 5-ODNs-rev on reverse transcriptase activity in vitro was evaluated with enzyme from disrupted HTLV-IHB particles and recombinant HTV-1 enzyme (Seikagaku Co., Tokyo, Japan) as described previously (19) . Briefly, RT assays were performed at 37°C for 60 min with 50 /il of a reaction mixture containing 50 mM Tris-HCl (pH 8.4), 2 mM dithiothreitol (DTT), 100 mM KC1, 10 mM MgCl 2 , 0.01% Triton X, 1.25 fid of 
Intracellular distribution of phosphorothioate oligodeoxynucleotides in MOLT-4 and MOLT-4/HTV-1 cells
MOLT-4 or MOLT-4/HrV-l HTLV .iiiB cells were incubated widi FITC-labeled 5-ODNs-rev, 5-dC20, 5-dT20, or 5-random (0.5 liM) at 37°C for 10, 30 and 60 min. Cells were washed 3 times with PBS and resuspended in 0.37% formaldehyde containing PBS and observed with a scanning confocal microscope (LSM-GB200, Olympus, Tokyo, Japan).
RESULTS

Anti-HIV-1 activity of oligodeoxynucleotides
A phosphorothioate-modified oligodeoxynucleotide with chain lengths of 20 bases, complementary to a region at the start of translation of rev-RNA (S-ODN-rev) inhibited virus replication in HTV-1-infected MT^4 cells. The oligomer at concentrations as low as 0.02-0.5 |iM showed complete protection against virus-induced CPE, whereas almost no cytotoxicity was observed even at 0.5 /iM of the compound. However, natural type (O-ODN-rev) and partially modified oligodeoxynucleotide (SO-ODN-rev) were not able to inhibit HTV-1 replication. 5-dT20 and 5-dC20 inhibited HTV-1 replication, but mild cytotoxicity was observed at the concentration of 0.5 jtM. Interestingly, 5-random was also able to protect against HTV-1-induced CPE, but its anti-HTV-1 activity was weaker than that of S-ODN-rev (Table 1) . 
Inhibition of viral expression in chronically HTV-infected cells by an antisense oligodeoxynucleotide
When MOLT-4/HIV-1 cells were cultured with S-ODN-rev for the first 2 days or second 2 days (day 2-4 after incubation), the amount of p24 was not different between the cell cultures with and without S-ODN-rev. The number of viable cells in the cell culture was eOxl^/ml to TSxlOVml on day 2 and 99 X lO^ml to 145 X KWml on day 4. However, after long-term culture, the amount of p24 decreased in the supernatant of MOLT-4/HIV-1 cells treated with 1 fiM of S-ODN-rev on day 20 after incubation ( Fig. 1) . The number of viable cells on day 20 was 28xl0 4 /ml, eSxKrVml, TOxK^/ml, 72xlO 4 /ml, and 82 X lO-Vml in the MOLT-4/HTV-1 cell culture with 10, 1, 0.1, 0.01 and 0 /M of S-ODN-rev, respectively, and that of MOLT-4 cells without S-ODN-rev was 85 X lCVml. Because the number of viable cells were adjusted at 30 X lO^ml on day 18, cell toxic effect was observed in the cell culture with 10 fiM of S-ODNrev. Therefore, the amount of p24 in the cells treated with 10 fiM of S-ODN-rev was significantly low but the reduction of p24 in the cells treated with 10 /iM S-ODN-rev might reflect cytotoxicity of the test compound.
Inhibition of RT activity
As shown in Table 2 , S-ODN-rev did not inhibit RT activity of either the recombinant enzyme or the enzyme from disrupted HTLV-HIB particles. When S-ODN-rev was added at high concentrations, such as 5-25 fiM, enzyme activity was not significantly altered as compared to the compound-free control. Therefore, S-ODN-rev participates through a mechanism of interaction different from that of the RT enzyme. When we tested the RT inhibitory activity of S-ODN-rev-sa, S-ODN-rev-sa-sense, and S-dC20, HIV-1 RT activity was not interacted, either (data not shown).
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Cellular uptake of [
P]-labeled S-ODN-rev in MOLT-4 cells
Unlike the use of endogenously transcribed or microinjected antisense oligodeoxynucleotides, regulatory activity of exogenous oligodeoxynucleotides appears to depend upon the uptake of sufficient amounts by the cells. As shown in Figure 2 , the The high level of cell-associated 5-ODN-rev was maintained at least until 48 h after incubation. However, under the experimental methods used here, we were unable to state unequivocally that the [ 32 P]-labeled 5-ODN-rev was incorporated into the cells rather than being tightly associated with the cell membranes. To address this question, further studies were carried out using FITC-labeled antisense oligodeoxynucleotides and confocal laser scanning microscopy.
Localization of oligodeoxynucleotides in MOLT-4 and MOLT-4/HTV-1 cells
FITC-labeled 5-ODN-rev was found in the cytoplasm of MOLT-4 cells 30 and 60 min after treatment (Fig. 3B and C) . Interestingly, FITC-labeled 5-ODN-rev was diffusely located in the cytoplasm of MOLT-4/HTV-1 cells 10 and 30 min after incubation and was located in the nucleus 60 min after incubation (Fig. 3D, E and  F) . At 60 min after incubation, FITC-5-dC20 and FITC-5-dT20 also accumulated in the nucleus of MOLT-4/HTV-1 cells (Fig.  4A-D) , but was located only in the cytoplasm of MOLT-4 cells.
Under microscopic observation, the fluorescence intensity of the FITC-5-oligodeoxynucleotides in MOLT-4 cells did not differ significantly between 30 and 60 min after incubation (other than a slightly decreased level at 60 min), whereas the intensity increased in MOLT-4/HIV-1 cells with time (Fig. 3) . In contrast to these observations, the fluorescence signals were observed at the cell membrane or in the cytoplasm very weakly in both FIT-C-5-random-treated MOLT^/HTV-1 and MOLT-4 cells (Fig. 4E  and F) . The microscopic observation of FITC-5-ODN-rev treated MOLT-4/HTV-1 cells at 2 h after incubation was not altered from that at 60 min. When FITC-OODN-rev or FITC-5O-ODN-rev was tested in MOLT-4/HIV-1 and MOLT-4 cells, visualable fluorescence signals were not observed.
DISCUSSION
Chemically modified nuclease-resistant oligodeoxynucleotide analogs have been developed and studied for their antiviral activity against HTV-1. Phosphorothioate oligodeoxynucleotides have been demonstrated to have anti-HIV-l activity in both acute infection (9, 14, 15) and in chronic infection in vitro (11, 16) . However, it is also known that even phosphorothioate-modified mismatched (random) oligomers and homooligomers have some inhibitory activity in acute HTV-l infected cells. In the acute virus infection system, an oligodeoxynucleotide and the virus may have more sites for mutual interaction than in the chronically infected cells. To enumerate these in the acute infection system, the oligomer may: i) interact with the virus prior to cell association of the latter; ii) compete or otherwise interfere with the virus-cell interaction at the cell surface; iii) interfere with membrane transport of the virus; iv) once inside the cell, compete with a nascent DNA chain for hybridization with the virus RNA strand; v) enhance or impair RNase H activity; and vi) interact with intracellular proteins.
In the present study, we found that 5-ODN-rev inhibited HIV-1-induced CPE, but O-ODN-rev and 50-ODN-rev failed to inhibit HTV-1 replication in acutely infected MT-4 cells in vitro. 5-dT20, 5-dC20 and 5-random also inhibited HTV-1-induced CPE. However, a superior inhibitory potency of 5-ODN-rev over the homooligomers and random sequence was observed. Lisziewicz et al. demonstrated that the sequence-specific antisense oligodeoxynucleotide phosphorothioates were more effective than non-sequence specific oligomers in the long-term treatment of HTV-infected cells (21, 22) . We also presented data that the phosphorothioate oligodeoxynucleotides inhibited HIV-1 production from chronically infected cells. In our experiment, 1.0 jiM of 5-ODN-rev exhibited regulational effects against HIV-1 gene expression by long-term treatment in M0LT-4/HIV-1 cells. Accordingly, we investigated the mechanism by which phosphorothioate oligodeoxynucleotides exert inhibition against HIV-1 replication, how oligodeoxynucleotides penetrate the cell and nuclear membranes, and where they are localized in the cultured cells.
Previously, we demonstrated that unmodified and phosphorothioate oligodeoxynucleotides prevented cDNA synthesis by avian myeloblastosis virus (AMV) or HTV RT. We also found that the phosphorothioate oligomer inhibited polymerization by binding to AMV RT rather than to the template RNA, whereas there was no competitive binding of the phosphorothioate oligomer on the HIV RT during reverse transcription (17) . In the present study, we demonstrated that S-ODN-rev did not affect the enzyme activity of either the recombinant HIV-1 RT or enzyme from disrupted HTLV-HJB particles. When we investigated whether S-ODN-rev inhibited viral adsorption to CD4-positive cells by the HIV binding assay (19, 23) , S-ODN-rev also failed to inhibit direct HIV binding (data not shown).
The present study showed that [ 32 P]-0-ODN-rev in the present study, might be due to their digestion by nucleases; in particular, SO-ODN-rev was digested by the enzyme in an endonucleolytic manner rather than exonucleolytic cleavage. Our previous data suggested that phosphorothioate substituted oligomer is exceedingly resistance to nuclease digestion (14) and S-ODN-rev was staible at 48 h after incubation.
In the observation of FITC-S-ODN-rev distribution in treated MOLT-4 cells by a confocal laser scanning microscope, diffuse fluorescence was apparently seen in the cytoplasm. This is in contrast to rapidly increasing of cell-associated radioactivity in MOLT-4 cells which were treated with [ (25) . In our present study, we have attempted to know if antisense oligodeoxynucleotides were taken up and accumulated in the HIV-1-infected cells. Interestingly, fluorescence signals were accumulated in the nuclear region of chronically infected MOLT-4/HTV-1 cells. The microscopic observation at 2 h after incubation with FTTC-S-ODN-rev was not significant altered from that at 60 min after incubation. Marti et al. reported the cellular uptake of phosphorothioate antisense oligomer against rev in a variety of hematopoietic cells and HeLa cells (26) . They found that a phosphorothioate oligomer was mainly localized within the cell nucleus and perinuclear organelles and little was in the cytoplasm or on the cell membrane. Taking this observation into account, we thought that S-ODN-rev could penetrate both MOLT-4 and MOLT-4/HTV-1 cells and that S-ODN-rev might hybridize to the target sequence of viral RNA, thereby becoming located in MOLT-4/HTV-1 cells, especially in the nuclear region. Because such target sequences do not exist in MOLT-4 cells, S-ODN-rev could neither hybridize nor remain in the cells for a long time. However, contrary to our expectation, fluorescence was apparently seen in the cytoplasm and accumulated in the nuclear region of MOLT^/HIV-1 cells when treated with S-dT20 and S-dC20 similar to the S-ODN-rev treatment. Because the sequence AAAA occurs 149 times in the whole HIV genome, and AAAAA occurs 50 times (11), S-dT20 may hybridize the HIV sequence more efficiently in MOLT-4/HIV-1 cells than its virus-negative counterpart. In addition, there are many G-rich sequence in HIV genome, thus S-dC20 may be retained in the cells, too. Of course, we cannot disregard the nonspecific binding of 5-dT20 and S-dT20 to intracellular proteins or cellular genomes. As shown in Table 1 , S-dT20 and 5-dC20 showed mild cytotoxicity at the concentration of 0.5 /*M, whereas no cytotoxicity was detected at the same concentration of S-ODNrev. The modest cytotoxicity of homooligomer may reflect nonspecific binding to cellular components. More interestingly, fluorescence accumulation in the nuclear region was not observed in S-random-treated MOLT-4/HTV-1 cells. It could be imagined that the random sequence failed to hybridize in our experiments. The pharmacokinetic study of S-oligonucleotide which was administrated intravenously or intraperitoneally to mice, was reported by Agrawal et al. (27) . Their results indicated that the 5-oligonucleotide was quite stable in most of the tissues, except the kidney and liver; in the plasma, stomach, heart and intestine, only 10-15% degradation was observed, and in kidney and liver, about 50% was degraded in 48 h. The antiviral activity of S-ODN-rev can be expected when administrated in HIV-infected individuals.
In summary, we demonstrated the cellular uptake and intracellular distribution of a phosphorothioate antisense oligodeoxynucleotide, S-ODN-rev, in chronically HTV-1-infected MOLT-4 cells. The present observations and our previous data (17) suggest that the S-ODN-rev exerts its anti-HIV-1 effect through a mechanism of interaction different from the inhibition of RT activity and HIV-1 binding to target cells directly. The anti-HIV-1 activity of S-ODN-rev is superior to that of the homooligomers, 5-dT20 and 5-dC20, and mismatched sequence oligomer, S-random. S-ODN-rev is also able to inhibit HIV-1 genome expression in chronically infected cells. The specific antisense oligodeoxynucleotides would appear to be more favorable therapeutic agents for HFV-1 infection.
